Metabolomics in Diabetic Retinopathy: From Potential Biomarkers to Molecular Basis of Oxidative Stress

作者

Jian, QZ; Wu, YJ; Zhang, F

作者单位

[Jian, Qizhi; Zhang, Fang] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Natl Clin Res Ctr Eye Dis, Sch Med, Shanghai 200080, Peoples R China; [Jian, Qizhi; Zhang, Fang] Shanghai Key Lab Ocular Fundus Dis, Shanghai 200080, Peoples R China; [Jian, Qizhi; Zhang, Fang] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai 200080, Peoples R China; [Jian, Qizhi; Zhang, Fang] Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai 200080, Peoples R China; [Wu, Yingjie] Dalian Med Univ, Natl Ctr Genetically Engn Anim Models Int Res, Inst Genome Engn Anim Models Human Dis, Liaoning Provence Key Lab Genome Engn Anim Models, Dalian 116000, Peoples R China; [Wu, Yingjie] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Prov Hosp, Sch Lab Anim, Jinan 250021, Peoples R China; [Wu, Yingjie] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Lab, Anim Ctr, Sci & Technol Innovat Ctr, Jinan 250021, Peoples R China; [Wu, Yingjie] NYU, Coll Dent, Dept Mol Pathobiol, New York, NY 10010 USA

摘要

Diabetic retinopathy (DR), the leading cause of blindness in working-age adults, is one of the most common complications of diabetes mellitus (DM) featured by metabolic disorders. With the global prevalence of diabetes, the incidence of DR is expected to increase. Prompt detection and the targeting of anti-oxidative stress intervention could effectively reduce visual impairment caused by DR. However, the diagnosis and treatment of DR is often delayed due to the absence of obvious signs of retina imaging. Research progress supports that metabolomics is a powerful tool to discover potential diagnostic biomarkers and therapeutic targets for the causes of oxidative stress through profiling metabolites in diseases, which provides great opportunities for DR with metabolic heterogeneity. Thus, this review summarizes the latest advances in metabolomics in DR, as well as potential diagnostic biomarkers, and predicts molecular targets through the integration of genome-wide association studies (GWAS) with metabolomics. Metabolomics provides potential biomarkers, molecular targets and therapeutic strategies for controlling the progress of DR, especially the interventions at early stages and precise treatments based on individual patient variations.

关键词

基本信息

所属机构:

归属医师: 吴英杰

PMID：36230967

UT：000866656800001

刊名:CELLS

年，卷(期):2022年11卷19期

页码：-null

DOI：10.3390/cells11193005

附件： other

收录: SCIE